about
Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance.Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia.Predicting treatment failure in patients with community acquired pneumonia: a case-control study.Nosocomial pneumonia in immunosuppressed patients.Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations.The microbiome in respiratory medicine: current challenges and future perspectives.Hypocapnia and hypercapnia are predictors for ICU admission and mortality in hospitalized patients with community-acquired pneumonia.Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids.Corticosteroids for pneumonia: are we there yet?Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission.Corticosteroids in severe pneumonia.Chromogranin A levels and mortality in patients with severe sepsisTHE PARADOXICAL EFFECT ON PNEUMONIA OF CHRONIC INHALED CORTICOSTEROIDS.Animal models of ventilator-associated pneumonia.The risk and outcomes of pneumonia in patients on inhaled corticosteroids.Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers.What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents).Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.The respiratory threat posed by multidrug resistant Gram-negative bacteria.Multidrug-resistant pathogens in patients with pneumonia coming from the community.Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.Diagnostic challenges of bronchiectasis.Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis.Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis.Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease.Experimental severe Pseudomonas aeruginosa pneumonia and antibiotic therapy in piglets receiving mechanical ventilation.Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization.Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia.Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood.The first tissue-engineered airway transplantation: 5-year follow-up results.High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis.Pulmonary nocardiosis in patients with COPD: characteristics and prognostic factors.Effects of glucocorticoids in ventilated piglets with severe pneumonia.Optimal positive end-expiratory pressure during pumpless extracorporeal lung membrane support.New biomarkers in community-acquired pneumonia: Another step in improving outcome prediction.
P50
Q27027259-4C755B48-4876-431D-AC3A-BD7C6FBB03E6Q33572569-09B6CCF5-9A6A-412E-A530-89D7416DA385Q33790645-DB95E832-6524-443B-9E6A-56E0BCFE9DAEQ33790733-59732D1A-4A92-477D-B518-4471F7FAF9D7Q33906338-B34A2CA2-F3BD-4587-9961-6535069477F1Q35685631-6005A0A3-20C6-49FB-AF1D-5C50429FAB19Q35768180-3024DD92-F342-4A9D-B22F-F581927F2000Q36345295-38E53320-8EE0-4894-8FEE-95B467FD99D4Q36388035-0DE9AE01-65A7-4A75-9F0D-AC61F0534DA6Q36406243-42D98361-1ACD-46F8-9AC7-1B9EF3A396E4Q36412382-397220C3-681F-4725-B215-8104C3099B94Q36565447-D937866E-6320-4860-A477-5FD021C32E34Q36767156-8EE6EE4B-0DF6-4C14-8CAF-C00308B853CCQ37231392-15EDE198-851F-478B-B57D-F8B53F2204DAQ37264816-E4F1F624-2F7C-4F14-BD06-C46FAA299C6FQ37308633-1FE68FC0-72F3-47EC-8597-860E7D950DEBQ37360866-2908C526-E20A-4738-9E0B-ECFCD8C32935Q37364624-18402DBB-1AB6-4D5B-872E-FC97C0972AEAQ38040130-048F725C-EAA0-4FA1-8D0E-646FAF87955DQ38080615-0CF42F74-368D-4267-99A8-DC0F7D2B2B9BQ38416149-BB5F3FF8-E908-4861-868F-ED140F117563Q38662137-F0B9FDB1-5A44-42F1-9301-39F157B75A5DQ38767165-FAA728EB-0B68-47DA-A27E-5A7CCA75A70CQ38788006-586E5CC8-1A4F-4AEE-B66F-56D27D287B9EQ38863961-A05F78ED-E1F8-4339-BC34-1A4352A2DC17Q39324925-C27E6E77-2F1D-4C4F-92D2-2C4CD1428A7DQ40172815-E3371715-F40C-4846-BC2A-3F82632E028AQ40174113-74E653F1-7461-4E9A-9458-67D4EF24444EQ40211870-2547BB36-BADC-4ADA-81FE-7C55D9C6B7F7Q40441932-82AA6F75-AB6A-429F-AA1D-F1CE350CFE13Q40789565-EBB4E8B2-68D8-4E22-8D50-F409B21ADA3BQ41109186-B1B4ABC2-883C-4035-9EF2-7D9938D3F79DQ41428636-4B38342F-D80D-4C08-8949-82D2A21693A1Q42688231-F15BBE68-08BA-40BE-8218-96388687D333Q43592851-B1436B15-BD7A-43DC-A755-FF890679864AQ45037013-16CA1DEA-BBDB-466D-AF8A-483B2E69BB6AQ46028621-66D1617B-5882-4A89-B554-AEDE8AB1F9AEQ46570673-292D1671-8913-4754-84F3-77AFBA4F7E91Q47268861-E7907842-3A7F-4D06-9B9D-DBB6B0667F9FQ47973173-49D8E243-6D4C-4E3D-94FC-A4FB8DD657F6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Oriol Sibila
@ast
Oriol Sibila
@en
Oriol Sibila
@es
Oriol Sibila
@nl
Oriol Sibila
@pt
Oriol Sibila
@sl
type
label
Oriol Sibila
@ast
Oriol Sibila
@en
Oriol Sibila
@es
Oriol Sibila
@nl
Oriol Sibila
@pt
Oriol Sibila
@sl
prefLabel
Oriol Sibila
@ast
Oriol Sibila
@en
Oriol Sibila
@es
Oriol Sibila
@nl
Oriol Sibila
@pt
Oriol Sibila
@sl
P1053
T-4366-2017
P106
P1153
8761639900
P21
P31
P3829
P3835
oriol-sibila
P496
0000-0002-4833-6713